ArticleNeural regeneration research2018
Puerarin ameliorates allodynia and hyperalgesia in rats with peripheral nerve injury.
Article in Neural regeneration research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- The Analgesic Potential of Litsea Species: A Systematic Review.Molecules (Basel, Switzerland) · 2024Pooled it
- Network Pharmacology and Experimental Validation Unravel How Puerarin Improves Chronic Postoperative Pain.Molecular biotechnology · 2026Article
- Endocannabinoid system modulation in acute, chronic, and neuropathic pain: reviewing experimental models, clinical evidence, and nanotechnology delivery.Metabolic brain disease · 2026Review
- Herbomineral Medicine Peedanil Gold Exerts Analgesia in Neuropathy by Moderating Inflammatory Response and TRP Channel Expression in Sprague Dawley Rat Surgical Chronic Constriction Injury Model.Pain research & management · 2025Article
- Regulation of transient receptor potential ankyrin 1 by traditional Chinese medicine drugs and their active ingredients.Frontiers in pharmacology · 2025Review
- Review
- From Plant to Chemistry: Sources of Antinociceptive Non-Opioid Active Principles for Medicinal Chemistry and Drug Design.Molecules (Basel, Switzerland) · 2024Review
- The Pharmacological Treatment of Neuropathic Pain in Children.Current neuropharmacology · 2024Review
- Analysis of the mechanism of propagated sensation along meridians based on gene expression profiles.Journal of traditional and complementary medicine · 2023Article
- Intestinal anti-inflammatory and visceral analgesic effects of aFrontiers in pharmacology · 2022Article
- Is TRPA1International journal of molecular sciences · 2019Review
- Effects of TRPA1 activation and inhibition on TRPA1 and CGRP expression in dorsal root ganglion neurons.Neural regeneration research · 2019Article
- Ameliorative effect of gallic acid in paclitaxel-induced neuropathic pain in mice.Toxicology reports · 2019Article
- Chondroitin sulfate produces antinociception and neuroprotection in chronic constriction injury-induced neuropathic pain in rats by increasing anti-inflammatory molecules and reducing oxidative stress.International journal of health sciencesArticle
- The neuropathic pain: An overview of the current treatment and future therapeutic approaches.International journal of immunopathology and pharmacologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Puerarin is a major active ingredient of the traditional Chinese plant medicine, Radix Puerariae, and commonly used in the treatment of myocardial and cerebral ischemia. However, the effects of puerarin on neuropathic pain are still unclear. In this study, a neuropathic pain animal model was created by partial sciatic nerve ligation. Puerarin (30 or 60 mg/kg) was intraperitoneally injected once a day for 7 days. Mechanical allodynia and thermal hyperalgesia were examined at 1 day after model establishment. Mechanical threshold and paw withdrawal latency markedly increased in a dose-dependent manner in puerarin-treated rats, especially at 7 days after model establishment. At 7 days after model establishment, quantitative real-time reverse transcriptase-polymerase chain reaction results showed that puerarin administration reversed mRNA expression of transient receptor potential vanilloid 1 (Trpv1) and transient receptor potential ankyrin 1 (Trpa1) in a dose-dependent manner in dorsal root ganglion neurons after peripheral nerve injury. These results suggest that puerarin dose-dependently ameliorates neuropathic pain by suppressing Trpv1 and Trpa1 up-regulation in dorsal root ganglion of neuropathic pain rats.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.